[{"id":"c372b4b4-4bc4-4fd8-9862-9add8d9bb685","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922100","created_at":"2021-01-18T19:17:47.256Z","updated_at":"2024-07-02T16:35:18.417Z","phase":"Phase 1/2","brief_title":"Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML","source_id_and_acronym":"NCT03922100","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NMS-088"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-21"}]